Lyso (bis) phosphatidic acid (LBPA) is a novel antigenic target in anti-phospholipid
syndrome (APS) and antibodies directed against LBPA (aLBPA) have been detected in sera …

Since the aCL test was first described, several reports have described the heterogeneity of
aPL, which binds to different anionic phospholipids, proteins, or to a phospholipid‐protein …

The diagnosis of seronegative antiphospholipid syndrome (APS) has been proposed for
patients with well-defined clinical APS but persistently negative for the routinely tested …

Thin-layer chromatography (TLC) is a nonquantitative technique, which has been employed
in the detection of antiphospholipid (aPL) antibodies. Antiphospholipid syndrome (APS) is …

Antiphospholipid antibodies (aPLs) are a heterogeneous family of antibodies found in
autoimmune disorders, infectious diseases, and other situations. The presence of different …

Some disease manifestations are associated with serum antiphospholipid antibodies (aPL)
in patients with systemic lupus erythematosus (SLE) in what has been termed …

Antiphospholipid syndrome (APS) is a clinical autoimmune disorder characterized by arterial
and/or venous thrombosis and/or pregnancy morbidity, associated with the persistence of …

The presence of lupus anticoagulant, moderate-to-high levels of IgG and/or IgM antibodies
to beta-2 glycoprotein I or cardiolipin in association with at least one of the two major clinical …

Background: Antiphosphatidylserine/prothrombin complex (aPS/PT) antibodies are
emerging as an important marker for antiphospholipid syndrome (APS). We aimed to …

The diagnosis of antiphospholipid syndrome (APS) relies on the detection of
antiphospholipid antibodies (aPL). Currently, lupus anticoagulant (LA), anticardiolipin (aCL) …